Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
Features and Benefits
This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Journal of chromatographic science, 50(8), 727-732 (2012-05-19)
Blonanserin is a novel atypical antipsychotic agent for the treatment of schizophrenia. Ethyl alcohol, isopropyl alcohol and toluene are utilized in the synthesis route of this bulk drug. A new validated gas chromatographic (GC) method for the simultaneous determination of
Psychiatry and clinical neurosciences, 65(4), 389-391 (2011-05-17)
The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). The charts of 32 consecutive patients with delirium in the ICU were
Three cases of schizophrenia showing improvement after switching to blonanserin.
Naohiro Kurotaki et al.
Psychiatry and clinical neurosciences, 65(4), 396-397 (2011-06-21)
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(6), 534-535 (2012-10-17)
Human psychopharmacology, 27(1), 90-100 (2012-01-27)
The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first-episode schizophrenia. Twenty-four antipsychotic-naïve patients with first-episode schizophrenia participated in the study. Blonanserin was given in an open-label design for 8 weeks.
We offer many products related to serotonin receptors for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
